肺癌患者化疗前后血清sIL-6R测定的临床意义

CLINICAL SIGNIFICANCE OF DETERMINING THE SERUM sIL-6R LEVEL IN PATIENTS WITH LUNG CANCER BEFORE AND AFTER CHEMOTHERAPY

目的 :通过检测肺癌患者化疗前、后血清中sIL - 6R水平 ,探索化疗前、后sIL - 6R在肺癌患者体内变化的规律 ,为评价疗效、判断预后寻找一个客观指标。方法 :健康对照组 2 0例 ,肺癌患者 2 0例 ,分别抽取空腹血 ,肺癌患者分别于化疗前、后抽血离心后 ,留取血清 ,用ELISA方法检测。结果 :对照组血清sIL - 6R水平为 4 6 .83± 6 .70 μg/L ;肺癌组化疗前、后血清sIL - 6R水平分别为 6 6 .2 0± 9.33μg/L和 2 8.90± 8.6 μg/L。经配对t检验 ,差异有显著性 (P <0 .0 0 1)。结论 :肺癌患者体内存在着sIL - 6R的异常表达。化疗前后血清sIL - 6R水平低于化疗前 ,而且低于对照组 ,提示化疗药物不但抑制了肿瘤细胞的增殖和生长 ,而且也抑制了人体的免疫系统 ,sIL - 6R与肺癌的发生、发展和转归密切相关。

Objective:To investigate the regularity of serum sIL-6R changes before and after chemotherapy and its relation with curative effect and prognosis.Methods:There were 20 health cases in the control group and 20 lung cancer cases in experimental group.Blood was taken from an empty stomach.The patients with lung carcer were sampled before and after chemotherapy.ELISA was used to determine the serum of those blood sample.Results:The serum level of sIL-6R in the control group was 46.83±6.70ng/ml;and in the lung cancer group 66.20±9.33ng/ml and 28.90±8.6ng/ml before and after chemotherapy respectively.The difference was significant by t-test ( P <0.001). Conclusions:Patients with lung cancer have an abnormal expression of sIL-6R.(The serum level of sIL-6R after chemotherapy was lower than before chemotherapy,and lower than that in the control group also).The results suggest that chemotherapy could suppress not only the growth of tumor cells,but also the immune system.sIL-6R is related with the onset,development and prognosis of lung cancer.